Oncology Medical News about Wilms tumor 1 gene mutations;risk of recurrence;young adults;acute myeloid leukemia

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia
Cancer, 06/24/09

Renneville A et al. - In a study to determine whether WT1 mutations are a predictor of poor outcome in pts with acute myeloid leukemia (AML), it was reported that WT1 mutations represent an adverse prognostic factor in young adults with AML. Prospective trials should confirm the clinical relevance of WT1 mutations in relation to other prognostic factors in pts with AML.

Methods

268 young adults (ages 15-50 yrs) with AML who were treated on the Acute Leukemia French Association 9802 trial were studied.
WT1 exon 7 and 9 mutations were screened retrospectively by polymerase chain reaction and direct sequencing.
Pts were assessed for presence of the fms-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD), FLT3-D835/I836, nucleophosmin 1 (NPM1), and CCAAT/enhancer binding protein α (CEBPA) mutations.

Results

WT1 mutations were identified in 14 pts (5%) and were associated with a younger age and an FLT3-ITD.
No mutation was detected in pts who had favorable cytogenetics.
Pts who had WT1 mutations had a shorter overall survival at 4 yrs (22% vs 56%) and a higher risk of recurrence at 4 yrs (82% vs 46%) vs pts who had wild-type WT1.
Within the subgroup of pts who had normal karyotype AML (n=106), WT1 mutation was identified as an independent adverse prognostic factor for risk of recurrence.

<< Previous
Multiple myeloma

Next >>
The diagnostic and prognostic utility of positron emission...